101 related articles for article (PubMed ID: 19212683)
21. [Eye Disorders Associated with S-1 Chemotherapy in Gastric Cancer Patients].
Fujii C; Kimura Y; Makari Y; Mikami J; Fujita J; Kamigaki S; Hayashi H; Yanagishita Y; Yasui Y; Ishizaka T
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1960-1962. PubMed ID: 28133189
[TBL] [Abstract][Full Text] [Related]
22. [Results of treatment of far advanced and recurrent stomach cancer with TS-1].
Johira H; Yunoki S; Kawata N; Watanabe N; Hachisuka Y; Kimura M; Uomoto M; Hatano H; Sanada E; Watanabe R; Ohmori K; Miyata N
Gan To Kagaku Ryoho; 2005 Feb; 32(2):195-9. PubMed ID: 15751632
[TBL] [Abstract][Full Text] [Related]
23. [Evaluation of S-1 for stage IV gastric cancer].
Kanazawa Y; Furukawa K; Yamada T; Shirakawa T; Fujita I; Kato S; Yokoi K; Uchida E
Gan To Kagaku Ryoho; 2011 Oct; 38(10):1619-22. PubMed ID: 21996955
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of S-1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404).
Imamura H; Kishimoto T; Takiuchi H; Kimura Y; Morimoto T; Imano M; Iijima S; Yamashita K; Maruyama K; Otsuji T; Kurokawa Y; Furukawa H
J Chemother; 2014 Feb; 26(1):57-61. PubMed ID: 24090674
[TBL] [Abstract][Full Text] [Related]
25. [S-1 monotherapy achieved twenty-month survival for peritoneal lavage cytology-positive gastric cancer patient undergoing noncurative resection].
Shimoyama S; Kiyokawa T; Nishida M; Seto Y
Gan To Kagaku Ryoho; 2012 Sep; 39(9):1411-4. PubMed ID: 22996780
[TBL] [Abstract][Full Text] [Related]
26. Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604).
Tahara M; Fuse N; Mizusawa J; Sato A; Nihei K; Kanato K; Kato K; Yamazaki K; Muro K; Takaishi H; Boku N; Ohtsu A
Cancer Sci; 2015 Oct; 106(10):1414-20. PubMed ID: 26250827
[TBL] [Abstract][Full Text] [Related]
27. [An investigation of TS-1 single-agent therapy administered as first-line therapy for unresectable advanced gastric cancer].
Nukaya H; Hirashima N; Tanaka Y; Endo M; Matsunaga S; Hasegawa I; Kato A; Sakakibara K; Sakamoto T; Kondo H
Gan To Kagaku Ryoho; 2005 Oct; 32(10):1421-6. PubMed ID: 16227741
[TBL] [Abstract][Full Text] [Related]
28. Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer.
Yamanaka T; Matsumoto S; Teramukai S; Ishiwata R; Nagai Y; Fukushima M
Gastric Cancer; 2007; 10(2):129-34. PubMed ID: 17577624
[TBL] [Abstract][Full Text] [Related]
29. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003).
Tanaka H; Kanda M; Morita S; Taguri M; Nishikawa K; Shimada M; Muguruma K; Koeda K; Takahashi M; Nakamori M; Konno H; Tsuji A; Hosoya Y; Shirasaka T; Yamamitsu S; Sowa M; Kitajima M; Okajima M; Kobayashi M; Sakamoto J; Saji S; Hirakawa K
Int J Clin Oncol; 2017 Dec; 22(6):1052-1059. PubMed ID: 28667408
[TBL] [Abstract][Full Text] [Related]
31. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
Ito S; Ohashi Y; Sasako M
BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
[TBL] [Abstract][Full Text] [Related]
32. Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination.
Osugi H; Takada N; Takemura M; Kaseno S; Lee S; Ueno M; Tanaka Y; Fukuhara K; Fujiwara Y; Kinoshita H
Oncol Rep; 2002; 9(4):811-5. PubMed ID: 12066214
[TBL] [Abstract][Full Text] [Related]
33. [Postoperative adjuvant chemotherapy for gastric cancer after the adjuvant chemotherapy trial of S-1 for gastric cancer in Hiroshima prefecture: results from a questionnaire survey and future challenges].
Yamaguchi K; Hirabayashi N; Ninomiya M; Shinozaki K; Hatanaka N; Matsuda H; Tanabe K
Gan To Kagaku Ryoho; 2013 Dec; 40(13):2555-9. PubMed ID: 24335369
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of postoperative radiotherapy concurrent with S-1 in patients with gastric cancer.
Qiu M; Peng XC; Bi F; Wang X; Li Q; Xu F; Li ZP; Shen YL; Liu JY; Zhao YQ; Cao D; Gou HF; Yang Y; Chen Y; Yi C
Med Oncol; 2015 Jul; 32(7):191. PubMed ID: 26025485
[TBL] [Abstract][Full Text] [Related]
35. Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer.
Ichikawa W; Terashima M; Ochiai A; Kitada K; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M
Gastric Cancer; 2017 Mar; 20(2):263-273. PubMed ID: 26884344
[TBL] [Abstract][Full Text] [Related]
36. [Alternate-day oral therapy with S-1 for adjuvant chemotherapy of gastric cancer].
Takebayashi K; Kawai Y; Tagi T; Matsumura M; Shimizu K; Yamamoto H; Mekata E; Tani T; Sato M
Gan To Kagaku Ryoho; 2012 Mar; 39(3):385-7. PubMed ID: 22421764
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer.
Wada M; Yamamoto M; Ryuge S; Nagashima Y; Hayashi N; Maki S; Otani S; Katono K; Takakura A; Yanaihara T; Igawa S; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Masuda N
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1005-11. PubMed ID: 22160350
[TBL] [Abstract][Full Text] [Related]
38. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.
Kinoshita T; Nashimoto A; Yamamura Y; Okamura T; Sasako M; Sakamoto J; Kojima H; Hiratsuka M; Arai K; Sairenji M; Fukushima N; Kimura H; Nakajima T
Gastric Cancer; 2004; 7(2):104-9. PubMed ID: 15224197
[TBL] [Abstract][Full Text] [Related]
39. Final results of a phase II study of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma.
Naito S; Tatsugami K; Shinohara N; Tomita Y; Mizokami A; Fujisawa M; Hashine K; Nishikido M; Nakagawa M; Tsukamoto T; Akaza H
Jpn J Clin Oncol; 2014 Feb; 44(2):122-6. PubMed ID: 24298041
[TBL] [Abstract][Full Text] [Related]
40. Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy.
Hosokawa A; Sugiyama T; Ohtsu A; Doi T; Hattori S; Kojima T; Yano T; Minashi K; Muto M; Yoshida S
J Gastroenterol; 2007 Jul; 42(7):533-8. PubMed ID: 17653648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
